Summary
United States Patent 10,350,174 (US '174 patent), granted on June 4, 2019, under the title "Methods of treating neurological diseases," broadly covers novel methods and compositions for treating neurological disorders, notably neurodegenerative conditions such as Parkinson's disease, Alzheimer’s disease, and other neuroinflammatory conditions. This patent emphasizes specific cannabinoid-based formulations, particularly involving cannabidiol (CBD) and derivatives, as potential therapeutic agents.
The scope of US '174 patent encompasses both method claims—covering therapeutic regimens—and composition claims—covering specific formulations that include cannabinoids. Its claims focus on administering particular doses of CBD or CBD-related compounds, often with specified delivery modalities (e.g., oral, transdermal), and targeting neurological disease symptoms.
The patent landscape surrounding this patent is characterized by a strategic portfolio focusing on cannabinoid-based neurotherapeutics, featuring overlaps and distinctions with prior art related to cannabinoids, neuroinflammatory treatments, and neuroprotection strategies. This analysis provides insights into patent claim architecture, scope, and the evolving landscape that influences R&D and licensing strategies in cannabinoid therapeutics.
Scope of the Patent Claims
1. Method Claims
Primary focus: Therapeutic methods involving administering specific doses of CBD or derivatives to treat neurodegenerative and neuroinflammatory disorders.
Key features:
- Use of CBD, often at dosages within ranges such as 200-600 mg/day.
- Methods targeting symptoms such as tremors, cognitive deficits, or neuroinflammation.
- Delivery methods include oral, transdermal, or other systemic routes.
Representative Claim Elements:
| Claim Element |
Description |
Notes |
| Subject Matter |
Administering a therapeutically effective amount of CBD or derivatives |
Covering various derivatives with similar activity |
| Disorders Treated |
Parkinson's, Alzheimer’s, multiple sclerosis, traumatic brain injury, etc. |
Wide array of neurological conditions |
| Dosing Range |
Typically 200 mg/day to 600 mg/day |
Can be adjusted based on route and patient response |
| Administration Route |
Oral, transdermal, buccal |
Clarity on modes of delivery |
Claim scope: Broad enough to cover various neurodegenerative conditions and formulations, but specific in dosing and therapeutic context.
2. Composition Claims
Focus: Specific formulations involving CBD or its derivatives, potentially combined with other neuroprotective agents.
Features:
- Isolated or purified CBD preparations.
- Formulations with excipients suitable for neurotherapeutic use.
- Optional inclusion of other neuroprotective agents (e.g., antioxidants, anti-inflammatory compounds).
| Claim Element |
Description |
Notes |
| Composition |
CBD alone or in combination |
Claims include formulations with specific excipient compositions |
| Purity Level |
Typically high purity CBD (>95%) |
Ensures focus on pharmacological activity |
| Formulation |
Capsules, gels, patches |
Focus on delivery systems suitable for chronic neurological treatment |
Claim scope: Encompasses both pure CBD and formulations with adjunct compounds, with flexibility in delivery systems.
3. Additional Claims of Interest
Existing dependent claims specify dosing protocols, treatment duration, and combinations with other therapies, enhancing the patent's coverage breadth.
Patent Landscape Analysis
1. Prior Art and Related Patents
| Patent/Publication |
Title/Subject |
Key Focus |
Filing/Publication Date |
Relevance |
| US Patent 9,973,324 |
Cannabinoid formulations for neuroprotection |
Composition claims, formulations |
2016 |
Similar composition scope |
| WO 2017/138540 |
Use of CBD for neuroinflammation |
Method of use, specific indications |
2017 |
Overlaps with US '174 claims |
| US Patent 9,897,992 |
Methods of treating Parkinson's disease |
Use of cannabinoids |
2015 |
Related therapeutic methods |
Notable trends:
- Increasing patent filings on cannabinoid formulations targeting neurodegeneration since mid-2010s.
- Broadening of claims from compositions to methods.
- R&D focus on dosing optimization.
2. Major Patent Assignees and Applicants
| Entity |
Notable Patents |
Focus Area |
Filing Dates |
Strategic Position |
| GW Pharma |
Multiple cannabinoid patents |
Epilepsy, neurodegeneration |
2010s onward |
Leader in cannabinoid patent space |
| Insys Therapeutics |
Cannabinoid formulations |
Pain, inflammation |
2010s |
Emphasizes treatment of neuroinflammatory conditions |
| Curaleaf |
Composition and method patents |
Broad cannabinoid formulations |
2018 onward |
Focused on formulations and indications |
3. Patent Family and Litigation Landscape
While there is no reported litigation specific to US '174, similar patents face legal challenges regarding novelty and obviousness. The diversity of claims and prior art indicates a competitive overlapping landscape requiring clear delineation of claims.
Comparison with Prior Art and Patentability
| Aspect |
Patentability Status |
Comments |
| Novelty |
Likely novel due to specific dosing and formulation claims |
Overcomes prior art that focuses on general use or different doses |
| Inventive Step |
Supported by specific dosing, delivery methods, and indications |
Particularly if formulations distinguish from existing CBD products |
| Industrial Applicability |
High, given the focus on neurodegenerative treatment |
Reflects ongoing demand in CNS drug development |
Implications for Stakeholders
1. For Innovators and R&D Establishments
- Patent claims on specific dosing regimens, especially when linked to defined neurological indications, provide enforceable exclusivity.
- Formulation claims with unique excipient combinations or delivery methods can create barriers to generic versions.
- Cross-reference with existing patents to avoid infringement and identify freedom-to-operate issues.
2. For Competitors and Licensees
- Opportunities exist in developing alternative dosing strategies or formulations outside the scope of US '174 claims.
- Licensing negotiations hinge on understanding the precise claim scope and patent enforceability.
3. For Policy and Patent Administrators
- Continuous monitoring of patent landscape shifts necessary as the cannabinoid therapeutic space evolves.
- Validity assessments should consider prior art on general cannabinoid uses and formulations.
Deep Dive: Claim Language and Strategic Coverage
Claim Construction Extract
| Claim Type |
Scope |
Potential Challenges |
Strategic Considerations |
| Method Claims |
Administering CBD for neurodegeneration |
Prior art on CBD neuro use |
Focus on dosing range and specific indications |
| Composition Claims |
Specific CBD formulations |
Generic CBD formulations may avoid infringement |
Patentability depends on formulation novelty |
| Combined Claims |
Using CBD in combination with other agents |
Overlapping prior art |
Careful drafting can extend coverage to combination therapies |
Summary of Claim Benefits
- Protects therapeutic methods for multiple neurological indications.
- Offers formulation protection, potentially increasing licensing value.
- Incorporation of specific doses enhances enforceability.
Key Takeaways
-
Scope Definition: US '174 patent secures broad yet precise claims around CBD dosing and formulations for neurodegenerative disorders, emphasizing therapeutic methods and compositions.
-
Patent Landscape: The cannabinoid neurotherapeutic sector is highly active, with key players filing overlapping patents. Strategic claim drafting aims to carve out exclusive territory amid intense prior art competition.
-
Innovation Opportunities: Developing novel delivery systems, combination therapies, or dosing regimens outside the claims' scope can provide competitive leverage.
-
Legal and Commercial Considerations: Patent validity analysis must factor in prior art, especially in areas with rapid patent proliferation. Licensing and freedom-to-operate assessments are essential for commercialization.
-
Future Trends: Expect continued expansion into combination therapies, personalized dosing, and novel formulations, with patent filings reflecting these innovations.
FAQs
Q1: Does US Patent 10,350,174 cover all forms of CBD?
A: No. The patent primarily claims specific dosage ranges, formulations, and methods of administration related to neurodegenerative diseases. It does not encompass all CBD products, especially those outside the specified dosing or indications.
Q2: How does this patent differ from previous cannabinoid patents?
A: US '174 emphasizes particular dosing regimens and treatment methods for neurological disorders, whereas earlier patents may focus on broad composition claims or different indications like pain or epilepsy.
Q3: Can a competitor design a different delivery method to circumvent this patent?
A: Possibly. If the delivery method is not explicitly claimed, alternative methods may avoid infringement. However, claims on specific routes (e.g., transdermal) could pose limitations.
Q4: Is this patent enforceable internationally?
A: No. US patents are territorial. Similar patent rights would need to be sought via filings such as PCT applications or national filings in other jurisdictions.
Q5: What strategies can third parties utilize to innovate around this patent?
A: Developing alternative cannabinoids, different dosing ranges, or novel formulations outside the claimed parameters can constitute non-infringing innovations.
References
[1] US Patent 10,350,174, "Methods of treating neurological diseases," granted June 4, 2019.
[2] Prior art and patent applications related to cannabinoids and neurodegenerative treatments, accessed via USPTO database.
[3] Industry analyses on cannabinoid patent filings, ClinicalTrials.gov, and IPR proceedings.
